Endocyte Dodges Class Action Over Cancer Drug Claims
An Indiana federal judge on Monday quashed a securities class action claiming Endocyte Inc. lied about the effectiveness of a cancer drug tied to a $1 billion deal with Merck &...To view the full article, register now.
Already a subscriber? Click here to view full article